Elevated levels of thymidine kinase 1 peptide in serum from patients with breast cancer by Carlsson, Lena et al.
ORIGINAL ARTICLE
Elevated levels of thymidine kinase 1 peptide in serum from patients
with breast cancer
LENA CARLSSON
1, ANDERS LARSSON
1 & HENRIK LINDMAN
2
1Department of Medical Sciences, Clinical Chemistry, University Hospital, Uppsala, Sweden, and
2Department of Oncology,
University Hospital, Uppsala, Sweden
Abstract
Objectives. Thymidine kinase (TK) has an important role in DNA synthesis and is thus related to cell proliferation and turn-
over. Traditionally, TK has been measured by enzymatic activity or radioimmunoassays. These assays are difficult to adapt
to random access instruments. The aim of this study was to evaluate a new immunological sandwich assay for detection of
TK peptides in serum from breast cancer patients.
Material and methods. Serum samples were collected from patients with breast cancer and stored frozen at  708C. The
samples were collected after surgery, after metastatic tumor recurrence and after chemotherapy due to tumour recurrence.
Patients’ serum samples were analysed by the TK enzyme-linked immunosorbent assay (ELISA).
Results. In receiver operating characteristics (ROC) analyses of TK1 for diagnosis of breast cancer, the area under the curve
(AUC) for samples collected four weeks after surgery was 0.56 (95% CI 0.47 0.65), for samples collected postsurgically
after tumour recurrence 0.73 (95% CI 0.65 0.80), and after chemotherapy 0.64 (95% CI 0.56 0.72).
Conclusions. This study indicates that the tumour proliferation marker TK has a potential as a serum marker in breast
cancer. Further studies are warranted to verify this observation.
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Introduction
Thymidine kinase (TK) (EC.2.7.1.21) is an enzyme
in the pyrimidine salvage pathway and catalyses the
phosphorylation of thymidine to thymidine mono-
phosphate (1). There are two forms of TK: a
cytosolic (thymidine kinase 1 (TK1)) and a mito-
chondrial one (TK2) (2). The level of TK1 is very
low in non-proliferating cells but increases dramati-
cally at late G1 to late S-phase/early G2 phase during
the cell cycle in proliferating cells and tumour cells.
This makes TK1 an interesting marker for cell
proliferation and tumour growth. In patients with
malignancies more than 95% of the TK1 activity in
serum is derived from the malignant cells (3). Thus,
serum TK1 should be a good marker for tumour cell
proliferation. Serum TK1 activity has been used to
monitor the extent of tumour metastasis and prog-
nosis in patients with acute leukaemia, chronic
leukaemia, Hodgkin’s and non-Hodgkin’s lym-
phoma, bladder carcinoma, and cervical carcinoma
(4 10). The most widely used TK1 assays are
radioimmunoassay techniques, discouraging their
routine clinical use. It is therefore important to
find non-radioactive alternatives to these assays.
Both monoclonal and polyclonal antibodies are
available against TK1. One of these antibodies is a
chicken anti-TK1 polyclonal antibody raised against
a 31-amino acid synthetic peptide (GQPAG
PDNKE NCPVP GKPGE AVAAR KLFAPQ, re-
sidues 194 225) corresponding to the C-terminal
part of human TK1 (3). This antibody has been
used to develop a sandwich enzyme-linked immu-
nosorbent assay (ELISA) for TK1.
Breast cancer incidence has approximately
doubled compared with 1960. The number of new
breast cancer cases in Sweden in the year 2001 was
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DOI: 10.1080/030097308026888356,569, resulting in an age-adjusted incidence of 138
per 100,000 women (11). The number of deaths
from breast cancer was 1,487, giving a mortality rate
of 30 per 100,000. Breast cancer represented 29% of
all new cancers in women, and for a Swedish woman
the lifetime risk of developing breast cancer is now
above 12% (11). Most new breast cancers are
detected in women aged 55 59 years. The incidence
of and mortality from breast cancer is markedly
higher in Western countries than in Asian or African
countries (12). The average annual age-standardized
breast cancer rate increase in Sweden has been 1.8%
during the last decade, but the mortality figures have
slowly decreased and are, despite the high incidence,
one of the lowest in Europe (13). The annually
increasing cure rate, since the late 1980s also
observed in the United States and the United
Kingdom, could have many explanations, but earlier
diagnosis and more efficient adjuvant therapies are
corner-stones that cannot be neglected (14).
A proliferation marker such as TK1 could
theoretically be used to distinguish between those
cancers that proliferate slowly and more malignant
forms that show rapid growth. The present report is
the first clinical evaluation of a new sensitive and
specific immunoassay (enzyme-linked immunosor-
bent assay, ELISA) for determination of thymidine
kinase 1 in serum from breast cancer patients.
Material and methods
Patients’ sera and control sera
Blood samples were collected from patients with
breast cancer treated at the Department of Oncol-
ogy, Uppsala University Hospital. Twenty-four sam-
ples were collected four weeks after surgery, 39
samples were collected after postsurgical tumour
recurrence, and 41 samples were collected after
chemotherapy. A group of 100 healthy blood donors
from Uppsala University Hospital Blood Bank were
used as controls. This study was approved by the
local Ethics Committees.
TK1 enzyme-linked immunosorbent assay (ELISA)
Samples were analysed using an ELISA kit for
thymidine kinase (TK1) (Arocell, Uppsala, Swe-
den). Briefly, the microtitre plates had been coated
with affinity-purified polyclonal chicken antibodies
specific for TK1 peptide, and the first step was to
add standards and samples to the wells. During the
subsequent incubation period TK1 present in stan-
dards and samples was bound to the immobilized
antibody.
The plate was washed four times, and a biotiny-
lated polyclonal antibody specific for TK1 was
added. After incubation and four washes, enzyme-
labelled streptavidin was pipetted into the wells, and,
following an incubation step and four washes, a
substrate solution was added and colour developed
in proportion to the amount of TK1 bound. The
colour development was subsequently stopped, and
the intensity of colour was measured by spectro-
photometry. Calculation of results was performed
according to manufacturer’s recommendations, and
TK1 concentration was expressed in U/L.
Statistical analyses
Receiver operating characteristics (ROC) curves
were plotted, and areas under the ROC curves
were compared for specificity and sensitivity in the
three breast cancer groups. Sensitivity (the ratio of
patients with breast cancer who were positive for the
variable) and specificity (the ratio of patients without
breast cancer who were negative for the variable),
negative predictive value (probability that the disease
is not present when the test is negative), and positive
likelihood ratio (ratio between the probability of a
positive test result given the presence of the disease
and the probability of a positive test result given the
absence of the disease) were also calculated. These
analyses were performed on MedCalc Software
(Mariakerke, Belgium). Statistical significance was
considered at PB0.05.
Results
Clinicopathological characteristics of the patients
Median value for the samples collected four weeks
after surgery was 7.05 U/L (range 0.8 130.8 U/L),
the median value for samples collected after post-
surgical tumour recurrence was 13.7 U/L (range
0.8 170.1 U/L), and median value for samples
collected after chemotherapy was 9.1 U/L (range
0.4 199.8 U/L).
The mean value for the controls was 5.78 U/L
(range 1.5 159.4 U/L).
Thymidine kinase 1 ELISA titres
Twenty-four samples were collected four weeks after
surgery. The accuracy of the TK1 ELISA to detect
breast cancer prior to surgery according to receiver
operatingcharacteristicsisgiveninFigure1.Thearea
under the curve (AUC) for this patient group was
0.56 (95%CI 0.47 0.65, P 0.34). The sensitivityof
Thymidine kinase 1 and breast cancer 117the assay was 33.3% and the specificity 89% using a
cut-off of 12.3.
Thirty-nine samples were collected upon post-
surgical tumour recurrence. The accuracy of the
TK1 ELISA to detect breast cancer in this patient
group according to receiver operating characteristics
is given in Figure 2. The AUC for this patient group
was 0.73 (95% CI 0.65 0.80, PB0.0001). The
sensitivity of the assay in this patient group was
64% and the specificity 86% using a cut-off of 11.0.
Forty-one samples were collected after che-
motherapy. The AUC after chemotherapy was 0.64
(95% CI 0.56 0.72, P 0.008) (Figure 3). The
sensitivity of the assay in this patient group was
53.7%andthespecificity79.0%usingacut-offof8.9.
Discussion
TK1 activity is low or absent in resting cells, starts to
occur in late G1 cells, increases in S- phase, and
disappears during mitosis. The cell cycle regulation
makes TK1 a highly interesting marker for cell
proliferation and as a marker for tumour growth.
Also, TK1-deficient mice have been shown to have
increased mutation rates (15). The role of TK1 in
tumour growth has led to the use of TK1 as a cancer
serum marker.
The present study shows that TK1 can be a
potential tumour marker in breast cancer patients.
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Figure 2. Receiver operating characteristics (ROC) curves for
thymidine kinase 1 (TK1) analysed in serum samples from
patients with breast cancer (n 39) collected after metastatic
tumour recurrence after surgery in comparison with healthy
controls (n 100). Area under the curve (AUC) 0.73, 95%
conﬁdence interval (CI) 0.65 0.80, PB0.0001.
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Figure 1. Receiver operating characteristics (ROC) curves for
thymidine kinase 1 (TK1) analysed in serum samples from
patients with breast cancer (n 24) collected four weeks after
surgery in comparison with healthy controls (n 100). Area under
the curve (AUC) 0.56, 95% conﬁdence interval (CI) 0.47 0.65,
P 0.34.
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Figure 3. Receiver operating characteristics (ROC) curves for
thymidine kinase 1 (TK1) analysed in serum samples from
patients with breast cancer (n 41) collected after chemotherapy
in comparison with healthy controls (n 100). Area under the
curve (AUC) 0.64, 95% conﬁdence interval (CI) 0.56 0.72,
P 0.0076.
118 L. Carlsson et al.This result could reasonably be explained by the fact
that the level and activity of TK1 are highly
dependent on the growth state and cell cycle phase
and that the transcription of the TK1 gene is
strongly induced in response to growth stimulation
in the S-phase (16 19).
The assay used in the present study is a non-
radioactive immunological alternative to the tradi-
tional TK1 radioimmunoassay. The assay could also
be adopted to fit the format of high throughput
immunoanalysers currently used in clinical labora-
tories. This would facilitate the use of TK1 as a
tumour marker. The anti-TK1 Immunoglobulin Y
(IgY) antibody used in the ELISA has previously
been characterized (3). Antibodies derived from egg-
yolk offer interesting advantages over mammalian
antibodies in several aspects and may sometimes be
a more suitable choice in designing solid-phase
immunometric assays than mammalian antibodies.
Chicken antibodies do not activate the human
complement system which is a well known source
of interference in sandwich immunoassays (20).
Capture antibodies bound to a solid surface are
potent complement activators, and the activated
complement components will react with the assay
antibodies thus partly blocking the antigen-binding
sites (21). Another advantage is that rheumatoid
factors (RF) do not bind to IgY. RF is a major source
of interference in many immunoassays, reacting with
the Fc portion of mammalian IgG (22). The disease
usually associated with RF is rheumatoid arthritis,
but RF is also present in blood samples from patients
with many other diseases and also healthy indivi-
duals (6,7). Most immunoassays use mammalian
polyclonal or monoclonal antibodies, which are
subjected to RF binding, thus potentially giving false
positive results. As RF is not able to bind to IgY,
chicken antibodies can be useful in assays (e.g.
nephelometry, turbidimetry, or ELISA) where RF
could interfere (22). Another interfering factor is
human anti-mouse IgG antibody (HAMA). An
increasing number of patients are in vivo treated
with monoclonal mouse antibodies, and this often
provokes an antibody response in the patient result-
ing in HAMA production. Chicken antibodies do
not react with HAMA, so they can be used to
eliminate such interference (23,24). Thus, chicken
antibodies should theoretically have advantages over
mammalian antibodies in immunoassays especially
for tumour marker assays as mouse monoclonal
antibodies are used for tumour treatment and this
treatment increases the prevalence of HAMA (24).
In conclusion, the current study has demon-
strated that the serum concentration of TK1 is
increased in patients with breast cancer. These
findings could provide the basis for future studies
of the clinical utility of the assay.
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